Chung-An Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chung-An Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Vin-Cent Wu
Division of Nephrology, Department of Internal Medicine National Taiwan University Hospital Taipei Taiwan
6 shared publications - Jui-Yi Chen
Division of Nephrology, Department of Internal Medicine Chi‐Mei Medical Center Tainan Taiwan
5 shared publications Wei-Jie Wang
Division of Nephrology, Department of Internal Medicine, Lo-Sheng Hospital, New Taipei, Taiwan
3 shared publicationsChung-Yi Cheng
Division of Nephrology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
2 shared publications- Chung-Yi Cheng
Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publication - Heng-Chih Pan
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102413
Validation of ICD-10-CM algorithms for repeated eGFR-defined chronic kidney disease in the TriNetX network
Objectives Chronic kidney disease (CKD) is increasingly identified using electronic health records for real-world research, yet the validity of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) CKD algorithms remains uncertain. We evaluated the diagnostic accuracy of ICD-10-CM algorithms against repeated estimated glomerular filtration rate (eGFR)-defined CKD in the TriNetX network.Methods Adults with ≥2 eGFR measurements between 2021 and 2025 in the TriNetX US Collaborative Network were included. Repeated eGFR-defined CKD served as the reference standard. Diagnostic performance of algorithms requiring ≥1 or ≥2 ICD-10-CM codes was assessed, with additional temporal analyses restricting code ascertainment to ±3, ±6 and ±12 months around the index eGFR measurement.Results Among 8 239 691 adults with ≥2 eGFR measurements, 1 328 952 met laboratory-defined criteria for CKD stage ≥3. For stage ≥3, an ICD-10-CM code yielded sensitivity of 64.1%, specificity of 95.6%, positive predictive value (PPV) of 73.8% and negative predictive value (NPV) of 93.3%. For stage ≥4, sensitivity was 79.2%, specificity was 98.0%, PPV was 57.3% and NPV was 99.3%. Requiring ≥2 codes reduced sensitivity but increased PPV. Temporal restriction increased PPV to approximately 96% for stage ≥3 and 93% for stage ≥4, but reduced sensitivity.Discussion Increasing the number of required ICD-10-CM codes and temporal restriction reduced sensitivity but increased PPV, highlighting trade-offs between diagnostic certainty and case ascertainment.Conclusions ICD-10-CM algorithms provide a valid but incomplete approach for identifying repeated eGFR-defined CKD in the TriNetX network. No single ICD-based phenotype or temporal ascertainment strategy is optimal; algorithm selection should therefore be guided by the research application. Future phenotyping strategies combining diagnosis codes with longitudinal laboratory data may further improve identification.
- 13 October 2026
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 33 (1) , e102413
Open AccessValidation of ICD-10-CM algorithms for repeated eGFR-defined chronic kidney disease in the TriNetX network
Objectives Chronic kidney disease (CKD) is increasingly identified using electronic health records for real-world research, yet the validity of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) CKD algorithms remains uncertain. We evaluated the diagnostic accuracy of ICD-10-CM algorithms against repeated estimated glomerular filtration rate (eGFR)-defined CKD in the TriNetX network.Methods Adults with ≥2 eGFR measurements between 2021 and 2025 in the TriNetX US Collaborative Network were included. Repeated eGFR-defined CKD served as the reference standard. Diagnostic performance of algorithms requiring ≥1 or ≥2 ICD-10-CM codes was assessed, with additional temporal analyses restricting code ascertainment to ±3, ±6 and ±12 months around the index eGFR measurement.Results Among 8 239 691 adults with ≥2 eGFR measurements, 1 328 952 met laboratory-defined criteria for CKD stage ≥3. For stage ≥3, an ICD-10-CM code yielded sensitivity of 64.1%, specificity of 95.6%, positive predictive value (PPV) of 73.8% and negative predictive value (NPV) of 93.3%. For stage ≥4, sensitivity was 79.2%, specificity was 98.0%, PPV was 57.3% and NPV was 99.3%. Requiring ≥2 codes reduced sensitivity but increased PPV. Temporal restriction increased PPV to approximately 96% for stage ≥3 and 93% for stage ≥4, but reduced sensitivity.Discussion Increasing the number of required ICD-10-CM codes and temporal restriction reduced sensitivity but increased PPV, highlighting trade-offs between diagnostic certainty and case ascertainment.Conclusions ICD-10-CM algorithms provide a valid but incomplete approach for identifying repeated eGFR-defined CKD in the TriNetX network. No single ICD-based phenotype or temporal ascertainment strategy is optimal; algorithm selection should therefore be guided by the research application. Future phenotyping strategies combining diagnosis codes with longitudinal laboratory data may further improve identification.
- Open Access
- 15 September 2026
- Published by SAGE Publications in Rare Tumors
- Vol. 18
Extragastrointestinal stromal tumor involving the adrenal region: A rare case report
Adrenal masses are increasingly detected due to advanced imaging modalities, yet their differential diagnoses remain broad and challenging. Extragastrointestinal stromal tumors (EGISTs) are rare mesenchymal tumors sharing histologic and immunophenotypic features with GISTs but occurring outside the gastrointestinal (GI) tract. EGISTs involving the adrenal region are exceptionally rare, with only five cases previously reported. In this case report, we present the sixth documented case, involving a male patient in his early 60s who presented with acute abdominal pain and a nonfunctioning retroperitoneal mass abutting the adrenal gland. Surgical resection and histopathological analysis confirmed a GIST with cluster of differentiation 117 (CD117) and Discovered on GIST-1 (DOG1) positivity. The patient received adjuvant imatinib and remained recurrence-free at two-year follow-up. This case highlights the diagnostic complexity of EGISTs involving the adrenal region and emphasizes the role of immunohistochemistry and surgical management. While early outcomes appear favorable, the rarity and limited follow-up data call for cautious interpretation and continued reporting to better define the prognosis and optimal treatment strategies.
- 15 September 2026
- Published by SAGE Publications in Rare Tumors
- Vol. 18
Open AccessExtragastrointestinal stromal tumor involving the adrenal region: A rare case report
Adrenal masses are increasingly detected due to advanced imaging modalities, yet their differential diagnoses remain broad and challenging. Extragastrointestinal stromal tumors (EGISTs) are rare mesenchymal tumors sharing histologic and immunophenotypic features with GISTs but occurring outside the gastrointestinal (GI) tract. EGISTs involving the adrenal region are exceptionally rare, with only five cases previously reported. In this case report, we present the sixth documented case, involving a male patient in his early 60s who presented with acute abdominal pain and a nonfunctioning retroperitoneal mass abutting the adrenal gland. Surgical resection and histopathological analysis confirmed a GIST with cluster of differentiation 117 (CD117) and Discovered on GIST-1 (DOG1) positivity. The patient received adjuvant imatinib and remained recurrence-free at two-year follow-up. This case highlights the diagnostic complexity of EGISTs involving the adrenal region and emphasizes the role of immunohistochemistry and surgical management. While early outcomes appear favorable, the rarity and limited follow-up data call for cautious interpretation and continued reporting to better define the prognosis and optimal treatment strategies.
- Open Access
- 9 September 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Sodium-glucose cotransporter-2 inhibitors, severe sepsis, and infection-related outcomes in patients with chronic kidney disease and type 2 diabetes
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are vulnerable to infections. While sodium-glucose cotransporter-2 (SGLT-2) inhibitors provide established cardiorenal benefits, their effects on infection remain unclear. This study aimed to evaluate the association between SGLT-2 inhibitors and the risks of severe sepsis, infection-related complications, and mortality in this population. We conducted a real-world, active-comparator, new-user cohort study using the U.S. Collaborative Network of TriNetX. Adults with CKD and T2D who initiated SGLT-2 inhibitors or DPP-4 inhibitors between 2018 and 2024 were included. Propensity score matching was applied to balance baseline characteristics. The primary outcome was severe sepsis; secondary outcomes included septic shock, mortality, hospitalization, pneumonia, urinary tract infection (UTI), and genital infection. After matching, 25,049 patients were included in each group. During 1 year of follow-up, SGLT-2 inhibitor use was associated with a lower risk of severe sepsis than DPP-4 inhibitor use (2.7% vs. 3.3%; HR, 0.81; 95% CI, 0.73-0.90). Risks of septic shock (HR, 0.83), mortality (HR, 0.72), hospitalization (HR, 0.90), pneumonia (HR, 0.77), and UTI (HR, 0.72) were reduced, whereas the risk of genital infection (HR, 1.93) was higher. No significant differences were observed in diabetic ketoacidosis or acidosis. Among patients with CKD and T2D, SGLT-2 inhibitor initiation was associated with lower risks of severe sepsis, infection-related outcomes, hospitalization, and mortality compared with DPP-4 inhibitor initiation, despite a higher risk of genital infection. These findings support SGLT-2 inhibitors as a core therapy with potential benefits extending beyond cardiorenal protection in this high-risk population.
- 9 September 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Open AccessSodium-glucose cotransporter-2 inhibitors, severe sepsis, and infection-related outcomes in patients with chronic kidney disease and type 2 diabetes
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are vulnerable to infections. While sodium-glucose cotransporter-2 (SGLT-2) inhibitors provide established cardiorenal benefits, their effects on infection remain unclear. This study aimed to evaluate the association between SGLT-2 inhibitors and the risks of severe sepsis, infection-related complications, and mortality in this population. We conducted a real-world, active-comparator, new-user cohort study using the U.S. Collaborative Network of TriNetX. Adults with CKD and T2D who initiated SGLT-2 inhibitors or DPP-4 inhibitors between 2018 and 2024 were included. Propensity score matching was applied to balance baseline characteristics. The primary outcome was severe sepsis; secondary outcomes included septic shock, mortality, hospitalization, pneumonia, urinary tract infection (UTI), and genital infection. After matching, 25,049 patients were included in each group. During 1 year of follow-up, SGLT-2 inhibitor use was associated with a lower risk of severe sepsis than DPP-4 inhibitor use (2.7% vs. 3.3%; HR, 0.81; 95% CI, 0.73-0.90). Risks of septic shock (HR, 0.83), mortality (HR, 0.72), hospitalization (HR, 0.90), pneumonia (HR, 0.77), and UTI (HR, 0.72) were reduced, whereas the risk of genital infection (HR, 1.93) was higher. No significant differences were observed in diabetic ketoacidosis or acidosis. Among patients with CKD and T2D, SGLT-2 inhibitor initiation was associated with lower risks of severe sepsis, infection-related outcomes, hospitalization, and mortality compared with DPP-4 inhibitor initiation, despite a higher risk of genital infection. These findings support SGLT-2 inhibitors as a core therapy with potential benefits extending beyond cardiorenal protection in this high-risk population.
- Open Access
- 7 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study
Objective: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in chronic kidney disease, but their effects in peritoneal dialysis (PD) patients who are infection prone, remain unclear. Study design: The study design of this research is target-trial emulation using the global federated electronic health record database. Adults (18–90 years) with type 2 diabetes on PD for ≥3 months between February 2015 and June 2025 were included. Propensity score matching balanced SGLT2i and nonuser. Primary outcomes were all-cause mortality, severe sepsis, sepsis, and pneumonia; secondary outcomes included major adverse cardiovascular events (MACE) and PD-associated peritonitis. Results: Among 29 529 eligible patients, 2815 (9.5%) received SGLT2i. After matching, 2749 patients were retained in each group with well-balanced baseline characteristics. Over a median follow-up of 0.79 years, SGLT2i users were associated with lower risks of all-cause mortality [adjusted hazard ratio (aHR) 0.818], severe sepsis (aHR 0.802), sepsis (aHR 0.661), pneumonia (aHR 0.664), and PD-associated peritonitis (aHR 0.340). MACE was not significantly different (aHR 0.798). SGLT2i was not associated with increased diabetic ketoacidosis, hypoglycemia, genital infection, volume depletion, or amputation. Conclusions: In this large real-world PD cohort with type 2 diabetes, SGLT2i use was associated with lower risks of death and major infections without safety concerns, supporting potential benefit pending randomized trial confirmation.
- 7 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Open AccessSafety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study
Objective: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular outcomes in chronic kidney disease, but their effects in peritoneal dialysis (PD) patients who are infection prone, remain unclear. Study design: The study design of this research is target-trial emulation using the global federated electronic health record database. Adults (18–90 years) with type 2 diabetes on PD for ≥3 months between February 2015 and June 2025 were included. Propensity score matching balanced SGLT2i and nonuser. Primary outcomes were all-cause mortality, severe sepsis, sepsis, and pneumonia; secondary outcomes included major adverse cardiovascular events (MACE) and PD-associated peritonitis. Results: Among 29 529 eligible patients, 2815 (9.5%) received SGLT2i. After matching, 2749 patients were retained in each group with well-balanced baseline characteristics. Over a median follow-up of 0.79 years, SGLT2i users were associated with lower risks of all-cause mortality [adjusted hazard ratio (aHR) 0.818], severe sepsis (aHR 0.802), sepsis (aHR 0.661), pneumonia (aHR 0.664), and PD-associated peritonitis (aHR 0.340). MACE was not significantly different (aHR 0.798). SGLT2i was not associated with increased diabetic ketoacidosis, hypoglycemia, genital infection, volume depletion, or amputation. Conclusions: In this large real-world PD cohort with type 2 diabetes, SGLT2i use was associated with lower risks of death and major infections without safety concerns, supporting potential benefit pending randomized trial confirmation.
- Top Cited PapersOpen Access
- 1 May 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (3) , 327-342
Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions
Diabetic acute kidney disease (AKD) represents a pivotal transitional phase between acute kidney injury (AKI) and chronic kidney disease (CKD), carrying a high risk of progression to end-stage kidney disease. Effective medical management is crucial during this phase. Renin-angiotensin-aldosterone system inhibitors remain the foundation of therapy, and newer agents have expanded the armamentarium. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have been shown to confer significant nephroprotective and cardioprotective effects, including decreased risks of AKD progression, heart failure, and mortality. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD, although its role in AKD remains uncertain. However, real-world data indicate the suboptimal utilization of these therapies, highlighting barriers related to clinical inertia, safety concerns after AKI, and socioeconomic disparities. Future strategies should emphasize the timely initiation and combination of treatments to maximize renoprotection, while exploring emerging agents such as endothelin receptor antagonists and aldosterone synthase inhibitors. Integrating evidence-based therapies, improving adherence to guideline-directed care, and leveraging real-world data to inform clinical practice are necessary to optimize kidney and cardiovascular outcomes in patients with diabetic AKD.
- 1 May 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 45 (3) , 327-342
Top Cited PapersOpen AccessMedical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions
Diabetic acute kidney disease (AKD) represents a pivotal transitional phase between acute kidney injury (AKI) and chronic kidney disease (CKD), carrying a high risk of progression to end-stage kidney disease. Effective medical management is crucial during this phase. Renin-angiotensin-aldosterone system inhibitors remain the foundation of therapy, and newer agents have expanded the armamentarium. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have been shown to confer significant nephroprotective and cardioprotective effects, including decreased risks of AKD progression, heart failure, and mortality. Finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, has also been shown to reduce kidney disease progression and cardiovascular events in patients with established diabetic CKD, although its role in AKD remains uncertain. However, real-world data indicate the suboptimal utilization of these therapies, highlighting barriers related to clinical inertia, safety concerns after AKI, and socioeconomic disparities. Future strategies should emphasize the timely initiation and combination of treatments to maximize renoprotection, while exploring emerging agents such as endothelin receptor antagonists and aldosterone synthase inhibitors. Integrating evidence-based therapies, improving adherence to guideline-directed care, and leveraging real-world data to inform clinical practice are necessary to optimize kidney and cardiovascular outcomes in patients with diabetic AKD.
- Top Cited PapersOpen Access
- 31 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation
The comparative effectiveness of finerenone and spironolactone in chronic kidney disease (CKD) with type 2 diabetes (T2D) remains unclear. Here we show, using a target trial emulation on global real-world data from TriNetX, outcomes among 2268 propensity score–matched adults with CKD (eGFR 15–60 mL/min/1.73 m²) and T2D who initiated finerenone or spironolactone between July 2021 and September 2024. Over a median follow-up of 1.3 years, finerenone is associated with lower risks of major adverse cardiovascular events (adjust hazard ratio [aHR], 0.74; 95% CI, 0.58–0.94), major adverse kidney events (aHR, 0.47; 95% CI, 0.33–0.67), all-cause mortality (aHR, 0.31; 95% CI, 0.21–0.45), and hyperkalemia (17.2% vs. 26.4%; P < 0.001) compared with spironolactone. These findings suggest potential benefits of finerenone over spironolactone in reducing mortality and cardiorenal risk among patients with CKD and T2D.
- 31 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Top Cited PapersOpen AccessFinerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation
The comparative effectiveness of finerenone and spironolactone in chronic kidney disease (CKD) with type 2 diabetes (T2D) remains unclear. Here we show, using a target trial emulation on global real-world data from TriNetX, outcomes among 2268 propensity score–matched adults with CKD (eGFR 15–60 mL/min/1.73 m²) and T2D who initiated finerenone or spironolactone between July 2021 and September 2024. Over a median follow-up of 1.3 years, finerenone is associated with lower risks of major adverse cardiovascular events (adjust hazard ratio [aHR], 0.74; 95% CI, 0.58–0.94), major adverse kidney events (aHR, 0.47; 95% CI, 0.33–0.67), all-cause mortality (aHR, 0.31; 95% CI, 0.21–0.45), and hyperkalemia (17.2% vs. 26.4%; P < 0.001) compared with spironolactone. These findings suggest potential benefits of finerenone over spironolactone in reducing mortality and cardiorenal risk among patients with CKD and T2D.